A Clinical Study of MK-3120 in People With Bladder Cancer (MK-3120-003)

Exclusion Criteria

• •Has history of or current locally advanced (ie, T2, T3, T4) or metastatic urothelial cancer (UC).
• •Has concurrent extravesical (ie, urethra, ureter, renal pelvis) non-muscle invasive UC or history of extravesical non-muscle invasive UC that recurred within the last 2 years.
• •Has active total bladder incontinence, active urinary tract infection, neurogenic bladder, or urethral stricture.
• •Has a condition that would prohibit normal voiding (or holding bladder voiding for 1 to 2 hours).
• •Has uncontrolled, significant cardiovascular disease or cerebrovascular disease, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of QTcF interval to \>470 ms, and/or other serious cardiovascular and cerebrovascular diseases within the 6 months preceding study intervention.
• •Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or severe corneal disease that prevents/delays corneal healing.
• •HIV-infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
• •Has known additional malignancy that is progressing or has required active treatment within the past 3 years.
• •Has known active central nervous system metastases and/or carcinomatous meningitis.
• •Has active infection requiring systemic therapy.
• •Has a history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids, or has current pneumonitis/ILD.
• •Has not adequately recovered from major surgery or has ongoing surgical complications.